Logo image of SMMT

SUMMIT THERAPEUTICS INC (SMMT) Stock Overview

NASDAQ:SMMT - US86627T1088 - Common Stock

26.94 USD
+0.67 (+2.55%)
Last: 8/26/2025, 11:53:03 AM

SMMT Key Statistics, Chart & Performance

Key Statistics
52 Week High36.91
52 Week Low11.76
Market Cap20.01B
Shares742.85M
Float116.63M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.38
PEN/A
Fwd PEN/A
Earnings (Next)10-28 2025-10-28/bmo
IPO10-14 2004-10-14
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


SMMT short term performance overview.The bars show the price performance of SMMT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

SMMT long term performance overview.The bars show the price performance of SMMT in the last 1, 2 and 3 years. 1 year 2 years 3 years 500 1K 1.5K 2K

The current stock price of SMMT is 26.94 USD. In the past month the price decreased by -4.3%. In the past year, price increased by 102.39%.

SUMMIT THERAPEUTICS INC / SMMT Daily stock chart

SMMT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.61 366.81B
AMGN AMGEN INC 13.23 155.39B
GILD GILEAD SCIENCES INC 14.78 141.97B
VRTX VERTEX PHARMACEUTICALS INC 22.7 98.60B
REGN REGENERON PHARMACEUTICALS 12.71 61.46B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.89B
ARGX ARGENX SE - ADR 75.18 42.65B
ONC BEONE MEDICINES LTD-ADR 6.2 36.49B
INSM INSMED INC N/A 27.67B
BNTX BIONTECH SE-ADR N/A 25.15B
NTRA NATERA INC N/A 22.54B
BIIB BIOGEN INC 8.49 19.92B

About SMMT

Company Profile

SMMT logo image Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 159 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Company Info

SUMMIT THERAPEUTICS INC

601 Brickell Key Drive, Suite 1000

Miami FLORIDA 02142 US

CEO: Robert W. Duggan

Employees: 159

SMMT Company Website

SMMT Investor Relations

Phone: 13052032034

SUMMIT THERAPEUTICS INC / SMMT FAQ

What is the stock price of SUMMIT THERAPEUTICS INC today?

The current stock price of SMMT is 26.94 USD. The price increased by 2.55% in the last trading session.


What is the ticker symbol for SUMMIT THERAPEUTICS INC stock?

The exchange symbol of SUMMIT THERAPEUTICS INC is SMMT and it is listed on the Nasdaq exchange.


On which exchange is SMMT stock listed?

SMMT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SUMMIT THERAPEUTICS INC stock?

18 analysts have analysed SMMT and the average price target is 35.19 USD. This implies a price increase of 30.62% is expected in the next year compared to the current price of 26.94. Check the SUMMIT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SUMMIT THERAPEUTICS INC worth?

SUMMIT THERAPEUTICS INC (SMMT) has a market capitalization of 20.01B USD. This makes SMMT a Large Cap stock.


How many employees does SUMMIT THERAPEUTICS INC have?

SUMMIT THERAPEUTICS INC (SMMT) currently has 159 employees.


What are the support and resistance levels for SUMMIT THERAPEUTICS INC (SMMT) stock?

SUMMIT THERAPEUTICS INC (SMMT) has a support level at 26.2 and a resistance level at 27.72. Check the full technical report for a detailed analysis of SMMT support and resistance levels.


Should I buy SUMMIT THERAPEUTICS INC (SMMT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SUMMIT THERAPEUTICS INC (SMMT) stock pay dividends?

SMMT does not pay a dividend.


When does SUMMIT THERAPEUTICS INC (SMMT) report earnings?

SUMMIT THERAPEUTICS INC (SMMT) will report earnings on 2025-10-28, before the market open.


What is the Price/Earnings (PE) ratio of SUMMIT THERAPEUTICS INC (SMMT)?

SUMMIT THERAPEUTICS INC (SMMT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.38).


What is the Short Interest ratio of SUMMIT THERAPEUTICS INC (SMMT) stock?

The outstanding short interest for SUMMIT THERAPEUTICS INC (SMMT) is 26.58% of its float. Check the ownership tab for more information on the SMMT short interest.


SMMT Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to SMMT. When comparing the yearly performance of all stocks, SMMT is one of the better performing stocks in the market, outperforming 95.15% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SMMT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SMMT. No worries on liquidiy or solvency for SMMT as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SMMT Financial Highlights

Over the last trailing twelve months SMMT reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS decreased by -72.73% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -50.81%
ROE -56.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-44.44%
Sales Q2Q%N/A
EPS 1Y (TTM)-72.73%
Revenue 1Y (TTM)N/A

SMMT Forecast & Estimates

18 analysts have analysed SMMT and the average price target is 35.19 USD. This implies a price increase of 30.62% is expected in the next year compared to the current price of 26.94.


Analysts
Analysts81.11
Price Target35.19 (30.62%)
EPS Next Y-189%
Revenue Next YearN/A

SMMT Ownership

Ownership
Inst Owners13.65%
Ins Owners84.32%
Short Float %26.58%
Short Ratio9.13